|
Dr. Brock’s research has focused primarily on developing and clinically applying molecular biomarkers, namely DNA methylation, to facilitate the early detection, accurate prognosis and specific chemosensitivity of lung and esophageal cancers. Current projects include using DNA methylation as a more accurate molecular indicator of lymph micrometases in a large cohort of lung cancer patients and as a means of predicting sensitivity of esophageal cancer to neoadjuvant chemotherapy based on endoscopic biopsy samples. Dr. Brock actively collaborates with Drs. Stephen Baylin and James Herman in the Division of Tumor Biology in the Cancer Center. Recently, Dr. Brock has received NIH funding to investigate the rising incidence of lung cancer in HIV patients and has begun both a clinical study and a tumor-profiling project in this regard. Finally, the Brock laboratory has developed large relational databases of lung and esophageal patients with matching biological samples to validate biomarker discovery. Malcolm V. Brock, MD, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center from TEAM DRAFT on Vimeo. |
Awareness • Early Detection • Treatment • Research • Survivorship